class of antidiabetic drugs, which include rosiglitazone and pioglitazone 4,5. PPAR-γ is prominently expressed in activated monocytes and tissue macrophages in vivo, including the foam cells of ...

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions ...

CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEM ...

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

At closing of the transaction, JASMIN shall acquire Pierre Fabre's R&D Centre (including R&D Site and R&D activities) at Saint-Julien-en-Genevois, France, and JBIRSPL would also execute a Shareholders ...

Community-acquired pneumonia (CAP) is a systemic disease and continues to be the leading cause of infectious mortality worldwide.1 Despite decades of advancements in patient care, mortality rates have ...

Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

In fact, the more we learn about biochemical pathways that this class of drug targets ... bringing white blood cells, or macrophages, rushing in, another sign of inflammation. (It’s rheumatoid rather ...